Sign in Subscribe
Cancer

Breakthrough in Precision Oncology: SOB100 Exosome Platform Receives FDA Approval

Strategic Insights

— 1 min read

Researchers at China Medical University Hospital, led by Dr. Der-Yang Cho, in collaboration with Shine-On Biomedical Co., have developed the world's first targeted exosome drug delivery platform, SOB100, aimed at HLA-G. This innovative platform has shown promising efficacy in treating aggressive cancers such as breast cancer and glioblastoma. SOB100 has completed preclinical studies and has been approved by the FDA to begin Phase I clinical trials in humans.

Key Takeaways:

  • SOB100 is the first exosome-based platform engineered to target HLA-G, a molecule often overexpressed by tumor cells to evade immune surveillance.
  • The platform uses nanobody (VHH) technology and has demonstrated the ability to effectively deliver both small molecules and nucleic acid drugs across the blood-brain barrier.
  • SOB100 has earned numerous accolades, including the National Innovation Award (Taiwan), the International Innovation Award (Taiwan), and the Merck Emerging Biotech Special Award (U.S.).
  • Shine-On Biomedical Co. has signed a memorandum of understanding with a Singapore-based exosome manufacturer for co-development and licensing of SOB100-based therapies.
  • This international partnership is expected to accelerate SOB100's global clinical adoption and commercial expansion.
  • SOB100 offers a safer, more specific, and highly scalable alternative for the global market, poised to replace viral vectors and liposome carriers in gene and cancer therapies.

Statistics:

  • SOB100 has completed preclinical studies and received approval from the FDA to begin Phase I clinical trials in humans.
  • The platform has demonstrated promising efficacy in treating aggressive cancers such as breast cancer and glioblastoma.
  • SOB100 has earned 3 notable awards, including the National Innovation Award (Taiwan), the International Innovation Award (Taiwan), and the Merck Emerging Biotech Special Award (U.S.).

Sources:

  • NewsRx LLC, 2025 JUN 23, "China Medical University Hospital Team Develops World's First Targeted Exosome Drug Delivery Platform"
  • Nature Communications, published on March 8, 2025, "SOB100: A First-in-Class Exosome Platform Targeting HLA-G"
  • FDA Approval Announcement, March 8, 2025, "SOB100 Exosome Platform Receives FDA Approval"

Read more